Samsung Bioepis gets OK to sell Flixabi in EuropeSamsung Bioepis got a green light from the European Commission to sell its biosimilar drug Flixabi in Europe, the company said on Monday. Flixabi is a biosimiliar product of Janssen’s Remicade.
Samsung already obtained a sales license in Korea for the same product called Renflexis, which treats rheumatis arthritis, ulcerative colitis, Crohn’s disease, spondylarthritis ankylopoietica and psoriatic arthritis. The drug had a market worth about 9 trillion won globally as of 2014.
The new drug will be sold in 31 European countries, including 28 EU member nations and three European Economic Community members - Norway, Iceland and Liechtenstein - with a price tag about 30 to 40 percent lower than Remicade.
Samsung Bioepis already sells another biosimilar product called Bennepali, which refers to the autoimmune disorder treatment drug
More in Industry
Move over Federer
Hanjin KAL slams largest shareholder, accusing it of peddling lies
Tech firms brief president on state of AI research
Dongsuh recognizes female authors at Scent of Life Awards